Exact Disappoints Investors With Cost Restructuring Plan; Seeks M&A Partner | GenomeWeb
After laying off most of its R&D staff and suspending a clinical trial for its Version 2 stool-based colon cancer test last week, Exact Sciences officials said the company’s top priority is finding an M&A partner who can bail it out of its cash flow problems.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.